TrialBreast cancer (Tokyo, Japan)2022

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Masato Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.